The research desk
Real-world dataThe whole class

A manufacturer's study says staying on Ozempic beat switching to Mounjaro. Read the asterisks.

Novo Nordisk's own real-world analysis reported fewer heart attacks, strokes and deaths in people who increased their Ozempic dose instead of switching drugs. It is interesting. It is also marketing-adjacent.

The side effects desk12 November 20261 min read

Novo Nordisk, which makes Ozempic and Wegovy, has released a real-world analysis comparing two choices for people with type 2 diabetes whose semaglutide dose was being increased: stay on semaglutide at the higher dose, or switch to tirzepatide (Mounjaro).

The comparison is lopsided by design. It looked at 185,705 adults who escalated to semaglutide 2 mg and 23,104 who switched to tirzepatide, and reported fewer major cardiovascular events — heart attack, stroke, death — in the semaglutide group, analysed on an intention-to-treat basis.

Here is the catch, and it is a big one. The people who switched were switching for a reason: their first drug wasn't working well enough, wasn't tolerable, or their clinician had a specific concern. That reason travels with them into the data. Observational comparisons like this cannot separate the drug from the person taking it, however large the numbers get.

It is also Novo's own analysis of its own product against a competitor's, released as a press release rather than a peer-reviewed paper. That does not make it wrong. It does mean the methods have not been through independent review, and that the framing was chosen by someone with a commercial interest in the answer.

A comparison of strategies is not a head-to-head trial, and the difference matters if you are the one deciding whether to switch.

What it found

  • 185,705 people who escalated to semaglutide 2 mg were compared with 23,104 who switched to tirzepatide.
  • The analysis reported fewer major cardiovascular events in the semaglutide group.
  • It was run and funded by Novo Nordisk, which makes Ozempic, and has not been peer reviewed.

What it can't tell us

Observational data cannot untangle the drug from the reasons someone switched, and nothing here was randomised. A company publishing a favourable analysis of its own product is normal — and exactly why you read the methods.

If you're on it

If you are weighing up a switch, this study should not be the thing that decides it. Ask your prescriber what the randomised evidence says for someone like you.

Sources

Every brief is written from scratch. We summarise and link rather than reproducing anyone's article, abstract, table or image, and any direct quote is short and attributed. Read the original before you draw conclusions from a summary — including ours. Not medical advice. If something feels wrong, speak to a clinician or call 111.